Synthesis and biological evaluation of cyclohexanpyridin-2(1H)-one analogues as novel HIV-1 NNRTIs

Gibrán Rodríguez-Vega 1,2, #, Julio Cesar Abarca-Magaña 3, #, Nancy Vanessa Castro-Perea 1, Mirna Berenice Ruiz-Rivera 3, José Luis Medina-Franco 4, Leonor Huerta-Hernández 3 and Daniel Chávez 1,*

1 National Technological of Mexico /Tijuana Technological Institute, Center for Graduate and Research in Chemistry, Postal Box 1166, Tijuana, Baja California 22000, Mexico.
2 Academic Unit of Chemical Biological and Pharmaceutical Sciences, Autonomous University of Nayarit, Tepic, Nayarit 63000, Mexico.
3 Biomedical Research Institute, Department of Immunology, National Autonomous University of Mexico, Mexico City 04510, Mexico.
4 DIFACQUIM Research group, Department of Pharmacy, School of Chemistry, National Autonomous University of Mexico, Mexico City 04510, Mexico.
# Authors contributed equally to this work.

World Journal of Advanced Research and Reviews, 2024, 22(03), 369–385

Abstract

In the search and development of new non-nucleoside reverse transcriptase inhibitor (NNRTI) compounds that are more effective against HIV-1, eight C-4 alkylated cyclohexanpyridinone derivatives of the alkyloxy and alkylamino type were synthesized. Compounds were characterized by spectroscopic and spectrometric techniques. In addition, their inhibitory effect against reverse transcriptase (RT), inhibition of HIV in vitro and cytotoxicity in JLTRG cells was evaluated. Compound 8e showed reasonable cellular antiviral activity (EC50 = 28.78 μM), moderate inhibition against RT (IC50 = 69.8 μM), and was not cytotoxic at the concentrations evaluated. Docking and molecular dynamics studies corroborate favorable binding to the HIV IT allosteric site with 8e, providing a basis for the design of more potent analogues.

Keywords: HIV-1; NNRTI; Reverse transcriptase; Pyridinones; Docking; Cytotoxicity; HIV infectivity; Molecular dynamics

1. Introduction

The Human Immunodeficiency Virus (HIV) is the causative agent of the Acquired Immunodeficiency Syndrome (AIDS) pandemic. According to UNAIDS data, there were 39 million people around the world living with HIV in 2022 [1]. Currently, a notable reduction in AIDS-related mortality has been made possible by highly active antiretroviral therapy (HAART). HAART targets multiple cycles of viral replication and includes two nucleoside reverse transcriptase inhibitors (NRTIs), a non-nucleoside reverse transcriptase inhibitor (NNRTIs), and a protease inhibitor (PI) or integrase inhibitor (INSTI) [2, 3]. One of the biggest challenges of HAART is that the virus can acquire drug resistance mutations, resistance arises as a result of poor patient adherence, allowing viral replication and mutation [4].

The development of specific inhibitors against the replication of HIV to reduce viral infection continues to be a leading treatment strategy against HIV [5, 6]. NNRTIs such as nevirapine and efavirenz (Figure 1) have been positioned as...
essential components in therapies combinations of drugs due to their unique antiviral activity, high specificity, and low toxicity [6, 7, 8].

A promising group of NNRTIs that has aroused the interest of researchers in recent years is that of compounds based on the pyridinone nucleus [9]. Merck's pyridinone (Figure 1) was the first potent and selective reverse transcriptase inhibitor of HIV-1 described from this group [10]. Using Merck's pyridinone nucleus, so-called first-generation compounds were developed, such as the pyridinone-HEPT hybrid, to which, however, HIV showed resistance. Rigidity is not desirable for NNRTIs, as they become ineffective due to most mutations, especially Y181C, Y188L and K103N [11, 12, 13]. Some internal flexibility and small size have been reported to be desirable to allow NNRTIs to be adjust to mutations; a perfect fit for wild type reverse transcriptase with a rigid inhibitor is not desirable [11, 12, 13].

A series of second-generation hybrids were synthesized to optimize Merck pyridinones against resistant strains, such as the hybrids pyridinone-HEPT, and pyridinone UC781 (Figure 1) [9]. Unlike introducing a substituent with an aromatic ring at C-4 as in HEPT-pyridinones, the strategy of including an aliphatic substituent at the same C-4 position was proposed in hybrids and pyridinone derivatives as UC781 [9]. The aliphatic substituent be intendent to perform interactions with conserved residues such as W229 and aromatic π–π interactions with Y181, although such interactions should be less significant compared to the aromatic π–π interactions of the original Merck pyridinones [14].

Here in, we report the design, synthesis, biological evaluation, docking and molecular dynamics (MD) of eight cyclohexanpyridinone derivatives as novel HIV-1 NNRTIs. The antiviral activities of all compounds were tested in HIV-1IIIB-infected JLTRG reporter cells and structure-activity relationships were established. We profiled the drug-like properties of the newly designed compounds and performed docking studies to gain insights into the binding modes of representative compounds and understand the biological potencies.

2. Material and methods

2.1. General Procedures

$^1$H and $^{13}$C NMR spectra of all compounds were collected on a Bruker Avance III spectrometer (400 MHz) and are expressed in ppm using TMS as an internal standard. The solvents used were CDCl$_3$ and DMSO. Electron impact ionization (EMIE) mass spectra were acquired on an Agilent Technologies 5975C. Functional group analysis by infrared (IR) spectroscopy was performed on a Fourier Spectrum 400 FT-IR infrared spectrophotometer, Pekin Elmer. The melting points were determined in a Fisher-Johns series 4114 apparatus. The percentage of fluorescent cells expressing the EGFP protein was measured by flow cytometry using the Attune Blue/Violet cytometer (Thermo Fisher, USA).
2.2. Synthesis of cyclohexanpyridin-2(1H)-one analogues

2.2.1. Ethyl 2-aminocyclohex-1-enecarboxylate (2)

Ethyl-2-oxocyclohexanecarboxylate (1) (25 g, 146.98 mmol) and ammonium nitrate (12.94 g, 161.67 mmol) were added in 150 mL of THF. The mixture was stirred for 5 d with bubbling ammonia for 30 min eight times a day. After this time, the solvent was removed, subsequently 150 mL of water was added, and the mixture was stirred for 30 min. The colorless residue was filtered and recrystallized in hexane to obtain compound 2 as a white solid. (24.34 g, 98%). Mp 61 °C IR (KBr): 3427, 3321, 2978, 2930, 2840, 1649, 1607, 1531 cm\(^{-1}\). \(^1^H\) NMR (CDCl\(_3\), 400 MHz) δ 6.00 (bs, N\(\text{H}2\)), 4.14 (q, J = 7.1 Hz, COOCH\(_2\)CH\(_3\)), 2.25 (t, J = 5.6 Hz, 2H, H-6), 2.20 (t, J = 6.0 Hz, 2H, H-3), 1.60 (m, 4H, H-4 y H-5), 1.27 (t, J = 7.1 Hz, COOCH\(_2\)CH\(_3\)). \(^1^3^C\) NMR (CDCl\(_3\), 100 MHz) δ 170.4, 156.4, 92.3, 58.8, 30.6, 23.4, 23.1, 22.2, 14.6. EIMS m/z (Rel. Ab): M\(^+\) 169 (80), 140 (90), 124 (60), 96 (100).

2.2.2. Ethyl 4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (3)

Metallic sodium (1.36 g, 59.14 mmol) was slowly dissolved in 20 mL of ethanol under nitrogen atmosphere. The mixture was heated to reflux and diethylaniline (3.0 g, 29.57 mmol) and potassium carbonate (2.53 g, 18.35 mmol) in 20 mL of THF was added. The mixture was stirred with reflux for 72 h to obtain a pale-yellow solution, which was cooled to room temperature and the precipitate filtered. The solid was then dissolved in ice water and acidified to pH 1 with a solution of concentrated solution of hydrochloric acid. The precipitate was filtered, washed with water and recrystallized with ethyl ether to obtain compound 3 as a white solid (6.0 g, 58%). Mp 205 °C IR (KBr): 3336, 3164, 3053, 2982, 2940, 2749, 1656, 1628, 1567 cm\(^{-1}\). \(^1^H\) NMR (DMSO-\(d_6\), 400 MHz) δ 13.45 (s, O\(\text{H}\)), 11.15 (s, N\(\text{H}2\)), 4.30 (q, J = 7.1 Hz, COOCH\(_2\)CH\(_3\)), 2.50 (t, J = 5.4, 2H, H-8), 2.30 (t, J = 5.3 Hz, 2H, H-5), 1.60 (m, 4H, H-6 y H-7), 1.30 (t, J = 7.1 Hz, COOCH\(_2\)CH\(_3\)). \(^1^3^C\) NMR (CDCl\(_3\), 100 MHz) δ 173.8, 172.5, 159.7, 150.9, 159.1, 96.4, 61.3, 26.9, 21.7, 21.3, 20.5, 14.6. EIMS m/z (Rel. Ab): [M\(^+\)] + 327 (45), 191 (45), 163 (75), 135 (100).

2.2.3. Ethyl 2-(benzoyloxy)-4-hydroxy-5,6,7,8-tetrahydroquinoline-3-carboxylate (4)

Compound 3 (5 g, 21.1 mmol) and silver carbonate (3.32 g, 12.03 mmol) were dissolved in 100 mL of THF; benzyl bromide in 20 mL of THF (3.59 g, 21.1 mmol) was added dropwise; the mixture was heated to reflux under nitrogen atmosphere for 8 h. The mixture was cooled to room temperature. The organic solution was then extracted with dichloromethane and then concentrated under reduced pressure to obtain compound 4 as a white solid (4 g, 58%). Mp 60 °C IR (KBr): 3372, 2987, 2939, 2815, 1646, 1623 cm\(^{-1}\). \(^1^H\) NMR (CDCl\(_3\), 400 MHz) δ 12.60 (br, s, O\(\text{H}\)), 7.50-7.29 (m, 5H), 5.40 (s, CH\(_3\)-Ar), 4.38 (q, J = 7.2 Hz, COOCH\(_2\)CH\(_3\)), 2.71 (t, J = 6.0 Hz, 2H, H-8), 2.57 (t, J = 6.4 Hz, 2H, H-5), 1.79 (m, 4H, H-6 y H-7), 1.34 (t, J = 7.2 Hz, COOCH\(_2\)CH\(_3\)). \(^1^3^C\) NMR (CDCl\(_3\), 100 MHz) δ 171.5, 169.2, 160.1, 159.5, 137.7, 128.1, 127.5, 127.4, 114.6, 94.6, 67.8, 61.6, 32.9, 22.6, 22.1, 21.6. 14.0. EIMS m/z (Rel. Ab): [M\(^+\)] + 327 (45), 149 (85), 91 (100).

2.2.4. (E)-ethyl 2-(benzoyloxy)-4-(but-2-en-1-yl)-5,6,7,8-tetrahydroquinoline-3-carboxylate (5a)

In a round bottom flask were added compound 4 (3.0 g, 9.17 mmol) and potassium carbonate (2.53 g, 18.35 mmol) in DMF. Crotlyl bromide (2.48 g, 18.35 mmol) dissolved in ethanol was added dropwise and the mixture was stirred at reflux under an inert nitrogen atmosphere for 48 h. The mixture was cooled to room temperature, filtered to remove salt and washed with acetone. The wash and filtrate were combined and evaporated to dryness. The residue was purified by silica gel column chromatography (dichloromethane/hexane, 9:1) to obtain an amber-yellow viscous liquid (2.97 g, 85%). IR, 3058, 3027, 2928, 1726, 1645 cm\(^{-1}\). \(^1^H\) NMR (CDCl\(_3\), 400 MHz) δ 7.41-7.25 (m, 5H), 5.80 (m, CH=CH\(_2\)), 5.67 (m, CH=CH-CH=), 5.38 (s, CH\(_2\)-Ar), 4.44 (dq, J = 6.2, 1.1, 1.1 Hz, CH\(_2\)-CH=CH=CH-), 1.60 (m, 4H, H-6 y H-7), 1.34 (t, J = 7.2 Hz, COOCH\(_2\)CH\(_3\)). \(^1^3^C\) NMR (CDCl\(_3\), 100 MHz) δ 166.2, 162.9, 158.6, 156.8, 137.7, 130.9, 128.2, 127.5, 127.4, 126.0, 118.7, 107.2, 73.6, 67.4, 61.4, 32.5, 22.8, 22.7, 22.4, 17.8, 14.1. EIMS m/z (Rel. Ab): [M\(^+\)] + 381 (14), 281 (16), 192 (21), 149 (38) 91 (100) um. a.

2.2.5. Ethyl-(E)-4-(but-2-en-1-yloxy)-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboylate (6a)

In a round bottom flask, the protected cyclohexanpyridinone-crotlyloxy hybrid 5a (1 g, 2.62 mmol) was placed in 100 mL of 1 N hydrochloric acid. It was left stirring, heating at 80 °C for 48 h; 5% sodium hydroxide was added until the solution was neutralized. A white precipitate formed, which was filtered, washed with acetone (0.38 g, 87%). \(^1^H\) NMR (CDCl\(_3\), 400 MHz) δ 7.72 (m, CH=CH-CH=), 5.55 (m, CH=CH-CH=), 4.41 (dq, J = 6.2, 1.1, 1.1 Hz, CH\(_2\)-CH=CH-CH=), 4.35 (q, J = 6.8 Hz, COOCH\(_2\)CH\(_3\)), 2.74 (t, J = 6.5 Hz, 2H, H-8), 2.57 (t, J = 6.5 Hz, 2H, H-5), 1.73 (m, 4H, H-6 y H-7), 1.80 (ddt, J = 6.2,
2.2.6. Ethyl 2-(benzylxylo)-4-((3-methylbut-2-en-1-yloxy)-5,6,7,8-tetrahydroquinoline-3-carboxylate (5b)

In a round bottom flask were added compound 4 (0.3 g, 0.92 mmol) and potassium carbonate (0.25 g, 1.84 mmol) in DMF. Dimethyllahyl bromide (0.2 g, 1.84 mmol) dissolved in DMF was added dropwise and the mixture was stirred at room temperature for 72 h. Later on, water (20 mL) was added and the aqueous layer was extracted with DCM (3 x 20 mL), the solvents were eliminated under vacuum to obtain compound 5b as a viscous yellow liquid (0.235 g, 65%). IR: 2972, 2934, 2860, 1725, 1666, 1574, 1099 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz) δ 7.42-7.24 (m, 5H), 5.45 (t, q, 7.2 Hz, 1.3 Hz CH=C=CH₂), 5.38 (s, CH₂=CH₂), 4.51 (d, 7.2 Hz, CH₂=CH=C=CH₂), 4.34 (q, J = 7.2 Hz, COOCH₂CH₃), 2.74 (t, J = 6.4 Hz, CH₃), 2.60 (t, J = 6.4 Hz, 2H, H-5), 1.80 (m, 4H, CH₂=CH-CH₂=CH₂), 1.76 (bs, CH₂-CH₂=CH₂=CH₂), 1.70 (bs, CH₂=CH-CH₂), 1.30 (t, J = 7.2 Hz, COOCH₂CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ 166.2, 163.0, 158.6, 156.7, 138.5, 137.7, 128.1, 127.4, 119.6, 118.7, 107.1, 69.6, 67.4, 61.3, 32.5, 25.7, 22.7, 22.6, 22.4, 18.0, 14.1. EIMS m/z (Rel. Ab): [M]+ 395 (3), 350 (9), 327 (71), 281 (34), 250 (23), 192 (26), 149 (76) 91 (100) umam.

2.2.7. Ethyl 4-((3-methylbut-2-en-1-yloxy)-2-oxo-1,2,6,7,8-hexahydroquinone-3-carboxylate (6b)

A solution of the compound 5b (0.15 g, 0.41 mmol) in 2N HCl (20 mL) was heated to reflux for 2 d. When the reaction was completed, the mixture was extracted with DCM (3 x 20 mL). The solvents were eliminated under vacuum to obtain compound 10. ¹H NMR (CDCl₃, 400 MHz) δ 5.41 (m, CH₂=C=CH₂), 4.56 (d, J = 6.8 Hz, CH₂=CH=CH₂), 4.37 (q, J = 7.2 Hz, COOCH₂CH₃), 2.59 (t, J = 6.0 Hz, 2H, H-8), 2.41 (t, J = 6.0 Hz, 2H, H-5), 1.70 (m, 4H, CH₃), 1.37 (t, J = 7.2 Hz, COOCH₂CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ 166.5, 165.6, 162.9 y 148.6, 144.5, 139.1, 119.1, 110.1, 68.7, 61.4, 29.6, 25.7, 22.1, 21.5, 21.4, 18.1, 14.1. EIMS m/z (Rel. Ab): [M]+ 305 (38), 285 (19), 259 (21), 191 (67), 163 (74), 149 (100) umam.

2.2.8. Ethyl 2-(benzoxyl)-4-((4-methylpent-3-en-1-yloxy)-5,6,7,8-tetrahydroquinone-3-carboxylate (5c)

In a round bottom flask were added compound 4 (0.3 g, 0.92 mmol) and potassium carbonate (0.25 g, 1.84 mmol) in DMF. Isopropenyl bromide (0.27 g, 1.84 mmol) dissolved in DMF was added dropwise and the mixture was stirred at room temperature for 72 h. Later on, water (20 mL) was added and the aqueous layer was extracted with DCM (3 x 20 mL). The solvents were eliminated under vacuum to obtain compound 5c as a viscous yellow liquid (0.37 g, 80%). ¹H NMR (CDCl₃, 400 MHz) δ 7.45-7.24 (m, 5H), 5.38 (s, CH₂=CH₂), 4.54 (m, CH₂=CH₂), 4.33 (q, J = 7.2 Hz, COOCH₂CH₃), 3.97 (t, J = 6.8 Hz, CH₂=CH=CH₂), 2.73 (t, J = 6.4 Hz, 2H, H-8), 2.57 (t, J = 6.4 Hz, 2H, H-5), 2.42 (dt, J = 7.2 Hz, 6.8 Hz, CH₂=CH=CH₂), 1.79 (m, 4H, CH₃), 1.70 (br, CH₂-CH₂-CH₂), 1.63 (bs, CH₂-CH₂-CH₂), 1.30 (t, J = 7.2 Hz, COOCH₂CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ 166.4, 162.8, 158.6, 156.6, 137.8, 134.5, 128.2, 127.5, 119.4, 118.3, 106.5, 72.2, 67.4, 61.4, 32.5, 29.1, 25.7, 22.8, 22.6, 22.5, 17.8, 14.1. EIMS m/z (Rel. Ab): [M]+ 409 (41), 364 (14), 327 (75), 281 (47), 250 (36), 192 (45), 149 (60) 91 (100) umam.

2.2.9. Ethyl 4-((4-methylpent-3-en-1-yloxy)-2-oxo-1,2,6,7,8-hexahydroquinone-3-carboxylate (6c)

A solution of the compound 5c (0.1 g, 0.24 mmol) in 2N HCl (20 mL) was heated to reflux for 2 d. When the reaction was completed, the mixture was extracted with DCM (3 x 20 mL). The solvents were eliminated under vacuum to obtain compound 6c. ¹H NMR (CDCl₃, 400 MHz) δ 5.11 (m, CH₂=C=CH₂), 4.36 (q, J = 7.2 Hz, COOCH₂CH₃), 4.03 (t, J = 6.8 Hz, CH₂=CH₂-CH₂=CH₂), 2.40 (t, J = 6.8 Hz, 2H, H-5), 2.30 (dt, CH₂=CH₂-CH₂=CH₂), 1.79 (m, 4H, CH₃), 1.70 (bs, CH₂=CH₂-CH₂), 1.36 (t, J = 7.2 Hz, COOCH₂CH₃). EIMS m/z (Rel. Ab): [M]+ 319 (20), 280 (6), 246 (27), 238 (32), 192 (100) 165 (86), 135 (45) umam.

2.2.10. 2-(benzoxyl)-4-(cyanomethoxy)-5,6,7,8-tetrahydroquinoline-3-carboxylate (5d)

Compound 4 (0.15 g, 0.46 mmol) and potassium carbonate (0.127 g, 0.92 mmol) were dissolved in DMF (20 mL). 2-bromoacetonitrile (2.96 g, 24.64 mmol) dissolved in DMF was added dropwise and the mixture was stirred at room temperature for 24 h. Later on, water (20 mL) was added and the aqueous layer was extracted with DCM (2 x 30 mL). The solvents were eliminated under vacuum to obtain compound 5d as a viscous brown liquid (0.14 g, 83%). IR: 3058, 2939, 2860, 1717, 1671, 1594, 1430, 1130 cm⁻¹. ¹H NMR (CDCl₃, 400 MHz) δ 7.42-7.26 (m, 5H), 5.39 (s, CH₂=CH₂), 4.78 (s, CH₂-CN), 4.36 (q, J = 7.2 Hz, COOCH₂CH₃), 2.78 (t, J = 6.0 Hz, 2H, H-8), 2.66 (t, J = 6.0 Hz, 2H, H-5), 1.80 (m, 4H, CH₃), 1.31 (t, J = 7.2 Hz, COOCH₂CH₃). ¹³C NMR (CDCl₃, 100 MHz) δ 165.1, 161.6, 158.9, 158.8, 137.3, 128.3, 127.6, 118.9, 115.0, 108.1, 67.9, 61.9, 58.3, 32.6, 22.5, 22.4, 22.1, 14.1. EIMS m/z (Rel. Ab): [M]+ 366 (22), 326 (18), 280 (38), 212 (69), 91 (100) umam.
2.2.11. Ethyl 4-(cyanomethoxy)-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (6d)

A solution of the compound 5d (0.1 g, 0.27 mmol) in 2N HCl (20 mL) was heated to reflux for 2 d. When the reaction was completed, the mixture was extracted with DCM (3 X 20 mL). The solvent was eliminated under vacuum to obtain compound 6d. 1H NMR (CDCl3, 400 MHz): δ 5.00 (s, CH2-CN), 4.42 (q, COOCH2CH3), 2.82 (t, 2H, H-8), 2.71 (t, 2H, H-5), 1.81 (m, 4H, H-6 y H-7), 1.39 (t, COOCH2CH3). EIMS m/z (Rel. Ab): [M]+ 276 (15), 270 (30), 247 (43), 229 (73), 73 (100) uma.

2.2.12. 4-chloro-5,6,7,8-tetrahydroquinolin-2(1H)-one (7)

Compound 3 (0.4 g, 2.42 mmol) and benzyl trimethyl ammonium chloride (2.20 g, 9.68 mmol) were dissolved in 10 mL of acetonitrile; phosphoric chloride (0.56 g, 3.63 mmol) was added dropwise. The mixture was stirred at room temperature for 24 h. Past this time, ice water was added and a white precipitated formed, which was filtered to obtain compound 7 as a white solid (92%). 1H NMR (CDCl3, 400 MHz): δ 4.41 (q, J = 7.2 Hz, COOCH2CH3), 2.66 (br, 2H, H-8), 2.53 (br, 2H, H-5), 1.78 (m, 4H, H-6 y H-7), 1.38 (t, J = 7.2 Hz, COOCH2CH3). RMN 13C (CDCl3, 100 MHz): δ 164.4, 160.6, 147.4, 146.1, 122.0, 113.8, 61.8, 27.1, 24.3, 22.2, 21.1, 14.1. EIMS m/z (Rel. Ab): [M]+ 255 (42), [M]+ 2 257 (14), 212 (19), 210 (60), 185 (27), 183 (100), 181 (51) uma.

2.2.13. Ethyl 2-oxo-4-(propylamino)-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (8e)

In a round bottom flask, compound 7 (50 mg, 0.196 mmol) and ethanol (15 mL) were added. Once stirring started, propylamine (0.064 mL, 0.784 mmol) was added drop by drop. The mixture was stirred for 48 h at reflux. Once the heating was completed, the mixture was cooled and concentrated in a rotary evaporator. Subsequently, the compound was purified by column chromatography with an ethyl acetate mobile phase to obtain a yellow liquid (45 mg, 82%). 1H NMR (CDCl3, 400 MHz): δ 11.37 (bs, NH), 6.30 (t, J = 7.2 Hz, NH-CH2-CH2-CH2-), 4.34 (q, J = 7.2 Hz, COOCH2CH3), 3.22 (q, J = 7.2 Hz, NH-CH2-CH2-CH2-CH3) 2.57 (br, 2H, H-8), 2.34 (br, 2H, H-5), 1.73 (m, 4H, H-6 y H-7), 1.61 ( sext, J = 7.2 Hz, NH-CH2-CH2-CH3) 1.37 (t, J = 7.2 Hz, COOCH2CH3), 0.96 (t, J = 7.2 Hz, NH-CH2-CH2-CH2-CH3). 13C NMR (CDCl3, 100 MHz): δ 169.4, 162.7, 158.0, 144.6, 104.7, 97.7, 60.7, 47.4, 27.2, 23.8, 23.6, 22.7, 21.2, 14.3. EIMS m/z (Rel. Ab): [M]+ 278 (43), 249 (20), 231 (35), 204 (60), 203 (100), 192 (40) uma.

2.2.14. Ethyl 4-(hexylamino)-2-oxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (8f)

In a round bottom flask, compound 7 (50 mg, 0.196 mmol) and ethanol (15 mL) were added. Once stirring started, hexylamine (0.10 mL, 0.784 mmol) was added drop by drop. The mixture was stirred for 48 h at reflux. Once the heating was completed, the mixture was cooled and concentrated in a rotary evaporator. Subsequently, the compound was purified by column chromatography with a mobile phase of ethyl acetate to obtain a yellow liquid (46 mg, 73%). 1H NMR (CDCl3, 400 MHz): δ 11.20 (bs, NH), 6.23 (bs, NH-CH2-CH2-(CH2)3-CH3), 4.34 (q, J = 7.2 Hz, COOCH2CH3), 3.24 (q, J = 7.2 Hz, NH-CH2-CH2-(CH2)3-CH3) 2.56 (br, 2H, H-8), 2.33 (br, 2H, H-5), 1.73 (m, 4H, H-6 y H-7), 1.58 (quint, J = 7.2 Hz, NHCH2-CH2-(CH2)3-CH3) 1.37 (t, J = 7.2 Hz, COOCH2CH3), 1.30 (m, 6H, NH-CH2-CH2-(CH2)3-CH3) 0.96 (t, J = 7.2 Hz, NH-CH2-CH2-(CH2)3-CH3). 13C NMR (CDCl3, 100 MHz): δ 169.4, 162.6, 157.9, 144.5, 104.6, 97.8, 60.7, 45.7, 31.4, 30.5, 27.2, 26.5, 23.6, 22.7, 22.5, 21.2, 14.3, 13.9. EIMS m/z (Rel. Ab): [M]+ ∙ 320 (36), 273 (27), 247 (26), 217 (30), 203 (100) uma.

2.2.15. Ethyl 2-oxo-4-(prop-2-yn-1-ylamino)-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (8g)

In a round bottom flask, compound 7 (50 mg, 0.196 mmol) and ethanol (15 mL) were added. Once stirring started, propargylamine (0.05 mL, 0.784 mmol) was added drop by drop. The mixture was stirred for 48 h at reflux. Once the heating was completed, the mixture was cooled and concentrated in a rotary evaporator. Subsequently, the compound was purified by column chromatography with an ethyl acetate mobile phase to obtain a yellow liquid (43 mg, 80%). 1H NMR (CDCl3, 400 MHz): δ 11.49 (bs, NH) 6.63 (t, J = 5.2 Hz, NH-CH2-), 4.36 (q, J = 7.2 Hz, COOCH2CH3), 4.02 (dd, J = 5.2 Hz, 2.4 Hz, NHCH2CH2) 2.60 (br, 2H, H-8), 2.40 (br, 2H, H-5), 2.32 (t, J = 2.4 Hz, NH2CH) 1.75 (m, 4H, H-6 y H-7), 1.37 (t, J = 7.2 Hz, COOCH2CH3). 13C NMR (CDCl3, 100 MHz): δ 169.0, 162.6, 157.9, 145.6, 105.3, 99.4, 80.1, 72.9, 60.9, 35.4, 27.1, 23.5, 22.6, 21.1, 14.2. EIMS m/z (Rel. Ab): [M]+ ∙ 274 (27), 245 (29), 227 (29), 205 (100), 203 (99) uma.

2.3. HIV-1 RT inhibition assays

Reverse transcriptase enzyme inhibition assays were performed in 96-well cell culture dishes using the EnzChek® Reverse Transcriptase Assay kit (invitrogen, USA) according to the user manual. In a microtubate, the dT and poly A18 oligos were aligned for 1 h, 10 µl of the mixture of aligned oligonucleotides was placed in each well, then the compounds were added at concentrations of 0.01, 0.05, 0.1, 4, 40 and 100 µM to subsequently add 0.625 units of a recombinant reverse transcriptase enzyme (Merck, Germany) diluted in enzyme diluent buffer (50mM Tris-HCl (pH 8.3, 25°C), 75mM KCl, 3mM MgCl2 and 10mM DTT). The experimental design included a negative control that contains all the elements necessary for the reaction except the reverse transcriptase and a positive control that contains all the components without any drug and an inhibition control with reference drugs (Efavirenz, Nevirapine); The reaction was carried out
for 45 minutes and was stopped by adding 200 mM EDTA. Subsequently, 173 μL of picogreen solution was added to the well, which is a dye that is specifically intercalated with the RNA-DNA or DNA hetero-duplex, which was incubated for 5 minutes at room temperature. The absorbance measurement was performed in a spectrophotometer. (BioTek, USA), the samples were excited at 485 nm and the measurement was performed at 520 nm.

2.4. Antiviral activity assay

Viral replication inhibition assays were carried out by seeding JLTRG cells in duplicate in 96-well cell culture dishes at a density of 50,000 cells/well, the compounds were added at concentrations of 0.01, 0.05, 0.1, 4, 40 and 100 μM and co-incubated for 1 h. Subsequently, the supernatant with virus suspended in 1X RPMI medium with 10% fetal bovine serum was added to obtain a concentration necessary to obtain an MOI of 0.1; The cultures were kept in incubation with the compounds and the virus at 37°C, 5% CO₂ and 95% atmospheric air for 48 h.

The samples were collected in microtubes where they were fixed with 2% paraformaldehyde for 30 minutes at 4°C, then two washes with 1X PBS were performed. The percentage of fluorescent cells that express the EGFP protein was measured by flow cytometry using the Attune Blue/Violet cytometer (Thermo Fisher, USA) using the blue laser (488 nm), the EGFP protein emits at 520 nm, using The BL1 detector detected the percentage of EGFP-positive cells. The determination of EC₅₀ was carried out in the Graphpad Prism version 6.0 program. A non-linear regression was carried out on the data obtained by creating a dose response curve for each compound. The data were normalized with respect to the control group: HIV-1 infected cells without treatment for in vitro infection.

2.5. Cytotoxicity evaluation

To measure cytotoxicity, the CellTiter 96® Non-Radioactive Cell Proliferation Assay kit from Promega (Madison, USA) was used in JLTRG cells quantifying the color change of 3-(4,5-dimethylthiazol-2-yl)-bromide. of 2,5-diphenyltetrazole (MTT), the presence of different concentrations of the synthesized compounds (0.01, 0.05, 0.1, 4, 40 and 100 μM). According to the procedure, JLTRG cells were seeded in the 96-well plate at a density of 50,000 cells/well and incubated at 37 °C in a 5% CO₂ incubator for 48 h. The incubated cells were treated with different concentrations of the compounds. After treatment, 20 μl of dissolved MTT at 5 mg/ml was added to each well and incubated for another 4 h. After incubation, the formed MTT-formazan crystals were dissolved in stopping solution (0.01N Tris HCl, 10% SDS) by adding 100 μl to each well. Finally, the plate was incubated in darkness for 5 min and the color change and absorbance were recorded at 570 nm using the iMarck plate reader from Bio-Rad (USA). The experiments were performed in triplicate. The determination of CC₅₀ was carried out in the Graphpad Prism version 6.0 program. A non-linear regression was carried out on the data obtained by creating a dose response curve for each compound. The data were normalized with respect to the control group: cells without treatment for the MTT assay.

2.6. In silico prediction of pharmacokinetic parameters

All the selected molecules were analyzed for the prediction of their pharmacokinetic parameters related to absorption, distribution, metabolism and excretion (ADME) using the SwissADME server [15], and evaluated using Lipinski’s rule of five for drug-likeness.

2.7. Molecular docking studies

The three-dimensional structures of the two receptors, HIV-1 reverse transcriptase and reverse transcriptase with the Y188L mutation, were retrieved from the Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) using PDB IDs: 2BE2 [16] and 1BQN [17], respectively. The receptors were prepared for molecular docking using Chimera software [18], where the water molecules, ions and other co-crystallized ligands present were removed using the protein preparation module present in the program. The synthesized compounds Molecular docking studies of the created compounds were carried out with the use of the program Autodock VINA [19, 20]. Through Autodock Vina and its graphical interface AutoDockTools 1.5.4 (ADT) non-polar hydrogens were eliminated and Gasteiger-Marsili charges were added. With the ADT program, using the AutoGrid 4.2 auxiliary program, the search box or grid was generated, which was positioned in the place of the co-crystallized ligand of the RT enzyme. The search for conformations accessible by the ligands was performed using AutoDock Vina with an exhaustiveness of 32 runs. Finally, the best docking models were selected, and two-dimensional docking maps created, which were designed using the Poseview server [21, 22] and the Discovery Studio Visualizer program [23]. The molecular docking protocol was validated by re-docking the co-crystallized ligand of the RT enzyme and evaluating of the RMSD value of its highest-ranking docked pose. The docking pose had a RMSD value of 1.001 Å.
2.8. Molecular dynamics

The ligand-protein complex of compound 8e with the RT enzyme obtained from molecular docking was subjected to MD simulation. The study was performed using GROMACS, version 2023.3 [24]. The complex was subjected to 100 ns dynamic simulation in an explicit water model using the CHARMM27 force field [25]. To represent water molecules, the TIP3P model was used [26]. The compound 8e topology file was created via SwissParam Server [27]. To mimic physiological conditions, 0.15 M salt (NaCl) was added. Before running production, the system was equilibrated by running 100 ps of NVT ensemble (isothermal-isochoric) and NPT (isothermal-isobaric). The simulation system was closely monitored to reach a temperature of 300 K and around 1 atmospheric pressure. MD simulations were then carried out in a triclinic box with a minimum distance of 1.0 nm between any atom of the protein and the walls of the box. The root mean square deviation (RMSD) of protein, root mean square fluctuation (RMSF) of amino acid residues, radius of gyration (rg), and hydrogen bonds were plotted using XMGRACE v5.1.19 [28].

3. Results and Discussion

3.1. Chemistry

Pyridinone derivatives were synthesized using the methodology described in Scheme 1. All compounds were synthesized from the common intermediate 3, which was conveniently prepared by condensation of ethyl 2-oxocyclohexanecarboxylate (1) with commercially available diethyl malonate [29]. In obtaining 6a-d the o-benzylaion of 3 was first necessary to obtain 4, which easily underwent the Williamson reaction [30] with the corresponding alkyl bromide to give 5a-d. The series of benzyl-protected esters were heated in aqueous HCl in order to debenzilate and provide 6a-d. The compound 6b is a pyridinone-UC781 hybrid. For the preparation of the amino analogues 8e-g, the pyridinone nucleus 3 was chlorinated with phosphorus oxychloride and benzyltriethylammonium chloride to obtain 7, finally substituting it in the C-4 position with different amines [29]. All substituted compounds were further purified by washing, recrystallized and then characterized by NMR, IR and MS. The performance of the molecules is reported with spectral data.

Scheme 1 Synthesis of cyclohexanpyridinone derivatives

Reagents conditions: (i) NH₄NO₃, THF anhydride, NH₃, 5d; (ii) diethyl malonate /EtONa/EtOH/reflux; (iii) PhCH₂Br, Ag₂CO₃, THF, reflux, 8 h; (iv) alkyl bromide, K₂CO₃, DMF, rt, 72 h; (v) HCl 0.75 N, rt, 48 h; (vi) POCl₃, benzyltriethylammonium chloride/CH₂CN/rt, 12h (vii) amine/EtOH/reflux, 48 h.
3.2. Pharmacokinetic parameters

Molecular weight (MW), octanol/water partition coefficient (log P), topological polar surface area (tPSA), water solubility (log S), hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), solubility (mg/mL) and number of rotatable bonds were calculated for the final synthesized compounds using the SwissADME server. Almost all the compounds showed good pharmacokinetic parameters and drug-like properties as contrived by Lipinski’s rule of five (Table 1).

Table 1 Predicted properties of the compounds selected for docking studies.

<table>
<thead>
<tr>
<th>Compound</th>
<th>MW</th>
<th>Rotatable bonds</th>
<th>HBA</th>
<th>HBD</th>
<th>TPSA</th>
<th>Log P</th>
<th>Log S</th>
<th>Solubility (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>381.46</td>
<td>9</td>
<td>5</td>
<td>0</td>
<td>57.65</td>
<td>4.58</td>
<td>-5.05</td>
<td>3.43E-03</td>
</tr>
<tr>
<td>6a</td>
<td>291.34</td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>68.39</td>
<td>2.67</td>
<td>-2.69</td>
<td>5.95E-01</td>
</tr>
<tr>
<td>6b</td>
<td>305.37</td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>68.39</td>
<td>3.09</td>
<td>-3.16</td>
<td>2.09E-01</td>
</tr>
<tr>
<td>6d</td>
<td>276.29</td>
<td>5</td>
<td>5</td>
<td>1</td>
<td>92.18</td>
<td>1.59</td>
<td>-1.99</td>
<td>2.81E+00</td>
</tr>
<tr>
<td>6c</td>
<td>319.4</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>68.39</td>
<td>3.33</td>
<td>-3.47</td>
<td>1.09E-01</td>
</tr>
<tr>
<td>8e</td>
<td>278.35</td>
<td>6</td>
<td>3</td>
<td>2</td>
<td>71.19</td>
<td>2.59</td>
<td>-2.99</td>
<td>2.84E-01</td>
</tr>
<tr>
<td>8f</td>
<td>320.43</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>71.19</td>
<td>3.61</td>
<td>-3.93</td>
<td>3.74E-02</td>
</tr>
<tr>
<td>8g</td>
<td>274.32</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>71.19</td>
<td>2.23</td>
<td>-2.54</td>
<td>7.88E-01</td>
</tr>
</tbody>
</table>

3.3. Molecular docking

This study aimed to provide a union model between the compounds and the 3D structure of the RT enzyme. Docking simulations were performed by energy minimization and optimization of the synthesized compounds at the binding site of the crystallized reverse transcriptase enzyme using PDB ID: 2BE2. This 3D structure was chosen due to the structural similarity of the co-crystrallized ligand with the synthesized pyridinones. The compounds docked at the allosteric site of the enzyme producing a similar binding pattern and positioning as the co-crystralized ligand R221239 (Figure 2). In addition, the docking of the compounds efavirenz and nevirapine was carried out to compare the results with these currently used drugs. The docking score (binding free energy, ∆G°, kcal/mol) of the designed pyridinones with the enzyme are summarized in Table 2

Figure 2 A) Superimpose of 8e (blue), 8f (green) and 8g (red) with co-crystralized ligand of 2BE2 (grey) in the binding site of RT; B) Interactions of the co-crystralized ligand R221239 with the RT enzyme.
Table 2 Docking scores of compounds with RT

<table>
<thead>
<tr>
<th>Compound</th>
<th>Vina Score (ΔG, kcal / mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>-8.0</td>
</tr>
<tr>
<td>6a</td>
<td>-8.5</td>
</tr>
<tr>
<td>6b</td>
<td>-9.6</td>
</tr>
<tr>
<td>6c</td>
<td>-9.0</td>
</tr>
<tr>
<td>6d</td>
<td>-7.5</td>
</tr>
<tr>
<td>8e</td>
<td>-8.5</td>
</tr>
<tr>
<td>8f</td>
<td>-8.7</td>
</tr>
<tr>
<td>8g</td>
<td>-8.5</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>-11.4</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>-7.4</td>
</tr>
<tr>
<td>R221239</td>
<td>-11.6</td>
</tr>
</tbody>
</table>

The molecular docking analysis of the synthesized pyridinones against RT highlighted compounds 6a, 6b, 6c, 8e, 8f and 8g with the most favorable docking values. The overlap of the docked poses of these ligands at the site of binding showed that they have a binding pattern and orientation similar to that of the co-crystallized ligand.

As shown in Figure 3, the interactions presented by compounds 6a, 6b and 6c, which contain alkenyloxy groups in R1, highlight the hydrogen bond with Lys101. This interaction is of vital importance for the anchoring of the compounds in the allosteric site of the RT [31]. On the other hand, interaction with Tyr188, an important interaction performed by the R221239 co-crystallized ligand, also stands out for the compounds.
Figure 3 Two-dimensional maps of the predicted interactions of the new pyridinones with RT. A) 6a, B) 6b, C) 6c.

The analysis of the predicted binding modes of compounds 8e, 8f and 8g, which contain amino groups in R1, with RT first showed that they were capable of generating hydrogen bond interactions with Lys101. Furthermore, the substituents on R1 showed interactions with Tyr188, similar to the R221239 co-crystallized ligand (Figure 4).

Figure 4 Two-dimensional maps of interactions with RT. A) 8e, B) 8f, C) 8g.

Additionally, the molecular docking of the compounds was carried out with the crystal structure of the RT which contains the Y188L mutation (PDB ID: 1BQN). This was done to analyze the interactions of the compounds in the face of such a mutation and observe the flexibility of the substituents to establish interactions in the allosteric site of the enzyme. The docking results of the eight synthesized compounds, as well as the compounds efavirenz and nevirapine,
are shown in Table 3. The analysis of the compounds was carried out by comparing the docking poses obtained superimposed to the co-crystallized ligand HBY 097 (Figure 5).

**Table 3** Energy score of the compounds against mutant RT.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Vina Score (ΔG, kcal / mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>-9.7</td>
</tr>
<tr>
<td>6a</td>
<td>-8.4</td>
</tr>
<tr>
<td>6b</td>
<td>-9.0</td>
</tr>
<tr>
<td>6c</td>
<td>-8.8</td>
</tr>
<tr>
<td>6d</td>
<td>-7.6</td>
</tr>
<tr>
<td>8e</td>
<td>-8.0</td>
</tr>
<tr>
<td>8f</td>
<td>-8.8</td>
</tr>
<tr>
<td>8g</td>
<td>-8.1</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>-9.4</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>-8.9</td>
</tr>
<tr>
<td>HBY 097</td>
<td>-7.7</td>
</tr>
</tbody>
</table>

**Figure 5** Interactions of the HBY 097 co-crystallized ligand in the mutant RT enzyme.
According to the predicted binding modes, the compounds make the key hydrogen bond interaction with Lys101 (Figure 6). Furthermore, in the Y188L mutation, the substituents in the C-4 position of the compounds were able to establish interactions with the Leu188 residue. Even the flexibility of the substituents allows them to interact with the Tyr181 residue (Figure 6).

3.4. Biological evaluation

3.4.1. Cellular cytotoxicity (MTT) of cyclohexanpyridinone derivatives

The cytotoxicity of cyclohexanpyridinone derivatives was evaluated by the percentage of viability using the MTT assay [32, 33] in Olaf Kutsch’s Jurkat LTR-GFP (JLTRG) cells donated by the NIH AIDS Reagent Program (EU). These are derived from the cell line Jurkat (immortalized T lymphocytes obtained from a patient with leukemia) [34] per well in the presence of increasing concentrations of the compounds (0.01-100 µM).

The results of the analysis of the 50% cellular cytotoxic concentration (CC50) showed that the molecules that have the amino substituent at C-4 8e and 8g have a CC50 >100 µM, therefore, they are not cytotoxic at the concentrations evaluated. Compound 8e showed the dose response curve in Figure 8A. The compound was not cytotoxic at the concentrations used, being less cytotoxic than efavirenz and nevirapine, which were the drugs used as controls. It is worth noting that derivative 8f showed to be highly cytotoxic (CC50 = 0-21 µM). These differences in cytotoxicity seem to be related to the chain length of the C-4 substituent, since 8e and 8g have a three-carbon chain while 8f has a six-carbon chain (Scheme 1).

Derivatives with an alkenyloxy substituent at C-4 6c and 6d were not cytotoxic at the concentrations used, with CC50 > 100 µM, while 6a and 6b were shown to be moderately cytotoxic (CC50 = 69 and 35 µM, respectively). Compound 5a showed moderate cytotoxicity (CC50 = 60 µM). Thus, the benzyl substituent in the C-2 position of compound 5a did not show to decrease cytotoxicity.
3.4.2. Reverse transcriptase inhibition assay

Inhibition of the compounds against RT was performed with the CellTiter 96® Non-Radioactive Cell Proliferation Assay kit from Promega (Madison, USA), as described by the manufacturer. The inhibitory concentration 50 (IC₅₀) was determined using the same increasing concentrations and culture conditions as the cytotoxicity assay. Efavirenz and nevirapine were used as positive controls. Evaluation of the inhibition of the compounds showed that cyclohexanpyridinone derivatives moderately inhibit reverse transcriptase activity and virus replication with inhibition percentages of 23 to 56% against RT activity. 5a showed inhibitory activity against RT of 23%, while compound 6a inhibited the enzyme in a concentration-dependent manner until reaching 40% inhibition at 100 µM, demonstrating the importance of the NH hydrogen of the pyridinone nucleus. Compound 8e also stands out (Figure 8B), with an IC₅₀ value of 69.8 µM, thus showing the best inhibition. The rest of the compounds showed no reverse transcriptase inhibitory activity at the concentrations tested, so the IC₅₀ values, if any, were >100 µM.

3.4.3. Anti-HIV and anti-RT activity of compounds

Table 4 Inhibition of RT activity, anti-HIV activity and cytotoxicity of cyclohexanpyridinone derivatives compared to efavirenz and nevirapine.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Substituent at C-4</th>
<th>CC₅₀ (µM)ᵃ</th>
<th>RT IC₅₀ (µM)ᵇ</th>
<th>HIV EC₅₀ (µM)ᶜ</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>Crotyl</td>
<td>60.0</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>6a</td>
<td>Crotyl</td>
<td>69.0</td>
<td>&gt;100</td>
<td>71.4</td>
</tr>
<tr>
<td>6b</td>
<td>Isopentenyl</td>
<td>35.0</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>6c</td>
<td>Isohexenyl</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>6d</td>
<td>Cyanomethyl</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>8e</td>
<td>Propyl</td>
<td>&gt;100</td>
<td>69.8</td>
<td>28.8</td>
</tr>
<tr>
<td>8f</td>
<td>Hexyl</td>
<td>0.02</td>
<td>&gt;100</td>
<td>&gt;3.9</td>
</tr>
<tr>
<td>8g</td>
<td>Propargyl</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Nevirapine</td>
<td></td>
<td>&gt;100</td>
<td>3.71</td>
<td>0.4217</td>
</tr>
<tr>
<td>Efavirenz</td>
<td></td>
<td>42.94</td>
<td>0.014</td>
<td>0.0046</td>
</tr>
</tbody>
</table>

ᵃCC₅₀ = Concentration required to reduce the viability of cell cultures by 50%, as determined by the MTT method; ᵇIC₅₀ = Concentration required to inhibit by 50% the in vitro of RT activity; ᶜEC₅₀ = Concentration required to inhibit HIV viral infectivity by 50%.

All cyclohexanpyridinone derivatives were evaluated in an in vitro infection model. The JLTRG reporter cell line infected by HIV-1 (strain IIIB) was used [34, 35, 36]. The IC₅₀ values for the cyclohexanpyridinone derivatives are shown in Table 4. Results showed that compounds 5a and 6b were cytotoxic at concentrations <100 µM and did not showed capacity to inhibit HIV infectivity. Compound 6a, which seemed to inhibit virus replication (IC₅₀ = 71.4 µM), had a CC₅₀ of approximately the same concentration (69 µM), so that virus inhibition may be due to the induction of cell damage by the compound and not to a specific antiviral effect. Notably, compound 8e had an IC₅₀ of 28.78 µM in the viral infectivity inhibition assay. In the dose-response curve (Figure 8C), it was observed that both nevirapine and compound 8e
inhibited the 75% of viral replication at the same concentration (100 μM). Importantly, as shown before, 8e showed low cytotoxicity (CC_{50} > 100 μM), an inhibited the activity of the RT (IC_{50} = 69.8 μM) (Figure 8B and Table 4).

3.5. Molecular dynamics simulation

Based on the results of the docking and biological tests, a MD simulation was carried out to predict the interactions and stability of compound 8e upon binding to the allosteric site of the RT.

The RMSD analysis indicates whether the simulation has equilibrated or not. Figure 9a shows the RMSD of the ligand when the protein-ligand complex is first aligned on the protein backbone of the reference molecule and then the RMSD of the ligand heavy atoms is measured. RMSD changes of the order of 0.1-0.3 nm are perfectly acceptable for small proteins, while much larger changes indicate that the protein is undergoing a large conformational change during the simulation [37]. In this study, the complex of 8e with RT was simulated for 100 ns. In Figure 9A it is observed that there was a small fluctuation in the RMSD value of the complex up to 10 ns, and then it converged and remained stable at 0.3 nm during the 100 ns duration of the MD simulation, which indicated that the complex of compound 8e with RT stabilized after 10 ns.

![RMSD](image1)

![Radius of gyration](image2)

![RMS fluctuation](image3)

![Hydrogen Bonds](image4)

**Figure 9** Stabilities of 8e in complex with RT during 100 ns MD simulation. A) RMSD values of the RT: 8e protein backbone complex. B) Rg (radius of gyration) of the RT: 8e complex as a function of time. C) RMSF values of amino acids of the RT: 8e complex. D) Number of intermolecular H bonds between 8e and RT.

The RMSF is an indicator of flexibility and shows local changes in protein structure. Since RMSF measures the deviations of the residue from its initial position, it is also very useful for exploring the conformational flexibility of protein-ligand complexes. As seen in Figure 9C, the compound maintained close contact with its binding site during the MD simulations.
The number of intermolecular hydrogen bonds is an important parameter that can be used to quantify the binding affinity between the protein and the ligand molecule. The presence of a large number of hydrogen bonds between the protein and the ligand means a strong bond between the molecules. Two hydrogen bonds were generally established in the complex during the 100 ns of simulation (Figure 9D).

4. Conclusions

With the aim of finding new HIV RT inhibitors containing a 2-pyridinone structure, pyridinone derivatives (5a, 6a-d) and other compounds with alkylated amino groups at the C-4 position (8e-g) were synthesized. A molecular docking analysis was performed showing that the pyridinone derivatives have a binding pattern and orientation similar to that of the co-crystallized ligand, in addition to similar scores to the drugs used as controls in the biological tests. Docking analysis also showed the potential of compounds to bind the Y188L mutant enzyme. Compound 8e showed moderate in vitro enzymatic inhibitory activity toward wild-type HIV RT, good activity against HIV strain IIIB, and is not cytotoxic for the human lymphocytic JLTRG cell line; therefore, it is the compound that had the best activity profile and can be classified as NNRTIs. In the MD results, 8e established two hydrogen bonds and good stability in the 100 ns of simulation, indicating a good affinity to the RT enzyme. Furthermore, 8e docking with a mutant RT enzyme showed flexibility of substituents to establish interactions at the allosteric site. This study stands out the relevance of the continuous search of synthetic small compounds against the HIV reverse transcriptase and their in vitro evaluation. Considering the findings of this study regarding the structural requirements and biological activity profiles of the tested compounds, further development of amino-type pyridinone-derived compounds similar to 8e (hit compound) will likely provide novel and more potent RT inhibitors for the treatment of HIV.

Compliance with ethical standards

Acknowledgments

We thank Consejo Nacional de Ciencia y Tecnología CONACyT, Grant 155029 to DC, and Dirección General de Asuntos del Personal Académico of Universidad Nacional Autónoma de México, Grant PAPIIT AG200623 to LH. GR-V acknowledges support from CONACyT in the form of graduate scholarship. We thank CONACyT for ITT NMR facilities (Grant INFR-2011-3-173395).

Disclosure of Conflict of interest

No conflict of interest to be disclosed.

References


